Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. Mech...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Pharmacol
Main Authors: Lichnog, Charlotte, Klabunde, Sha, Becker, Emily, Fuh, Franklin, Tripal, Philipp, Atreya, Raja, Klenske, Entcho, Erickson, Rich, Chiu, Henry, Reed, Chae, Chung, Shan, Neufert, Clemens, Atreya, Imke, McBride, Jacqueline, Neurath, Markus F., Zundler, Sebastian
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367223/
https://ncbi.nlm.nih.gov/pubmed/30774593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00039
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki